Anticoagulation on Demand in Paroxysmal Atrial Fibrillation After Percutaneous Coronary Intervention

• Status: Not yet recruiting
• Trial end date: 2021-11-30
• Target enrollment: 0
• Participant gender: All

Summary

Preliminary experiences suggest that intermittent anticoagulation guided by continuous electrocardiographic monitoring can reduce the incidence of bleeding in patients with episodes of atrial fibrillation.

Uncertainty about the potential implications of a strategy of intermittent anticoagulation after percutaneous coronary intervention exists.

The investigators will perform a pilot randomized trial to evaluate the safety and efficacy of anticoagulation on demand in patients with paroxysmal atrial fibrillation after percutaneous coronary intervention.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Roma La Sapienza
• Treatments: Apixaban; Dabigatran; Edoxaban; Rivaroxaban

Criteria

Inclusion Criteria:

• No chronic atrial fibrillation

• Coronary artery disease

• Percutaneous coronary intervention

Exclusion Criteria:

• Contraindications to anticoagulation

• Pregnancy